Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
33 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
1Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Mr. Fraser served as President and Chief Executive Officer from February 2016 until December 1, 2024, and as Chairman of the Board from June 2023 to January 2025. He brings over 30 years of experience in drug development, fundraising, business development and commercial operations, with prior roles at Novelion, Pfizer, Wyeth Pharmaceuticals, Johnson & Johnson, and Centocor.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Waters Corporation

2026-01-01 · current

Confirmed by public sourceView source

Director

Seres Therapeutics, Inc.

2023-01-01 · current

Confirmed by public sourceView source

Director

Becton Dickinson

2006-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Becton Dickinson

Open Becton Dickinson profile →

Director at Becton Dickinson

2006-01-01 → End not stated

current · source reported

Observed: 2026-09-21

Becton DickinsonBecton DickinsonSeres Therapeutics…Seres Therapeutics, Inc.Waters CorporationWaters CorporationCraig E. Fraser

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingWAT DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open sourceSource 2 · Sec FilingBecton, Dickinson and Company director board sourceSupports Board membership, Committee assignments, Board independence.Open sourceSource 3 · Sec FilingWINT 10-K executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 4 · Sec ProxyPublic profile sourceSupports Director at Seres Therapeutics, Inc. (NASDAQ: MCRB).Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:claire-m-fraser
Record version
public-0

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board independence · Source reportedIndependent director1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · Source reportedServes on the board of Becton Dickinson1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Becton, Dickinson and Company1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Board membership · Source reportedServes on the board of Seres Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Waters Corporation1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Committee assignments · Source reportedNo committee assignment disclosed in the cited filing1 source
Verification
Source reported
Confidence
95%
Last reviewed
May 3, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

Committee assignments · Source reportedCommittee assignments: Technology1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 6, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · Source reportedExecutive at WINDTREE THERAPEUTICS INC /DE/1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: Director1 source
Verification
Source reported
Confidence
94%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · CorroboratedTechnology background reported in filingsSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources9 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 6, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1000697/000119312526149657/d71187ddef14a.htm

    Sec Proxy · Tier not stated · Reviewed May 3, 2026

    Supports: Director at Waters Corporation (NYSE: WAT)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 3, 2026

    Supports: Board membership · Committee assignments · Board independence

  4. https://www.sec.gov/Archives/edgar/data/10795/000162828025057846/bdx-20251217.htm

    Sec Proxy · Tier not stated · Reviewed Mar 23, 2026

    Supports: Director at Becton Dickinson (NYSE: BDX)

  5. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  6. https://www.sec.gov/Archives/edgar/data/1609809/000095017025038441/mcrb-20250313.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Seres Therapeutics, Inc. (NASDAQ: MCRB)

  7. https://www.sec.gov/Archives/edgar/data/1000697/000119312526149657/d71187ddef14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  8. https://www.sec.gov/Archives/edgar/data/1609809/000095017025038441/mcrb-20250313.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  9. https://www.sec.gov/Archives/edgar/data/10795/000162828025057846/bdx-20251217.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership